CAMAGÜEY.- A total of 28 people, of 94 evaluated in Camagüey, have been included to be favored with the clinical trial of NeuralCIM (nasal drops) in patients with the phenotype of suffering from Alzheimer's, with the purpose of stopping the disease.
Bachelor Judith Ojeda de Pedro, Assistant Professor and Coordinator of Clinical Research at the Manuel Ascunce Domenech University Hospital, in this city, where the study is being carried out, announced that the age of the patient does not matter but the diagnosis of suffering from Alzheimer's does, being in mild or moderate phase, to which 0.25 milligrams (0.5 ml) will be applied to each nostril three times a week, that is, Monday, Wednesday and Friday, always at home and through the use of syringes to insulin.
The interested parties and their families come to the investigation after being evaluated in their areas of Primary Health Care (PHC) by specialists in Geriatrics and Neurology, and in the consultations known as dementia screening, located at the Amalia Simoni clinical surgical teaching hospital, also from this city, and which opens its doors every Thursday. Something very important to say is that each step is taken under informed consent, since participation in the clinical trial is completely voluntary.
A re-consultation is scheduled for week 52; however, at the initiative of the specialists involved here, they are checked again in the sixth month, although contact is not lost with either the patient or the caregiver.
Those who present vascular dementia, psychiatric diseases, such as: schizophrenia and bipolar disorder, unstable angina, acute myocardial infarction, cancer, Parkinson's disease, just to mention a few cases, are excluded from the research; nevertheless, they continue their treatments according to their conditions, they are never left without medical attention.
Dr. Odalmis Chacón Borrero, specialist in Geriatrics and Gerontology, and in Comprehensive General Medicine (MGI), Master in Clinical and Educational Neuropsychology, and Principal Investigator, announced that during the study blood tests, control of vital signs, neuropsychological examinations and other interrogations, and noted that the majority of these examinations are used in routine clinical practice.
She also said that Alzheimer's disease is the most common form of dementia among older adults that seriously affects the person's ability to carry out daily activities, and begins slowly, and with a countless details that are taken into account in the aforementioned consultations.
The NeuralCIM, a product conceived at the Center for Molecular Immunology (CIM), in the capital, is available to those who need it in all Cuban provinces because the clinical trial is carried out throughout the country and there is no preconceived number of people for its use, but on the contrary, it is used in anyone who qualifies for research.
Due to the multidisciplinary nature that is needed, in addition to the aforementioned specialists, doctors Leonor Porto Franco (Geriatrician and Gerontologist), Náyade Pérez Rodríguez, Nayime Navas Nápoles and Tatiana Rodríguez Báster (Neurologists), and the graduates in Psychology Eduardo Zayas Suárez and Reidel Chorus Good.
Translated by Linet Acuña Quilez